Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 5, 2014, Pages 906-914

  Takeuchi, Satoshi ^a   Khiewvan, Benjapa ^a,b   Fox, Patricia S ^a   Swisher, Stephen G ^a   Rohren, Eric M ^a   Bassett, Roland L ^a   Macapinlac, Homer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Clinical stage; Impact; Management plan; Non small cell lung cancer; Prognostic value

Indexed keywords

BIOLOGICAL ORGANS; DIAGNOSIS; DISEASES;

CLINICAL STAGE; FDG PET; HIGH IMPACT; IMPACT; MANAGEMENT PLANS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGNOSTIC VALUE; PROGRESSION FREE SURVIVAL; STAGE MANAGEMENT;

MULTIVARIANT ANALYSIS;

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR GROWTH; AGED; COMPUTER ASSISTED TOMOGRAPHY; LUNG TUMOR; MIDDLE AGED; MULTIMODAL IMAGING; NON SMALL CELL LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROGNOSIS; SCINTISCANNING;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84899095092     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2672-8     Document Type: Article

References (27)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727-40.
3. Dillemans B, Deneffe G, Verschakelen J, Decramer M. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients. Eur J Cardiothorac Surg. 1994;8:37-42.
4. Hicks RJ, Kalff V, MacManus MP, Ware RE, Hogg A, McKenzie AF, et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596-604.
5. Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol. 2001;19:111-8.
6. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998;16:2142-9.
7. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker Jr S, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330-53.
8. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359:1388-93.
9. Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:1943-51.
10. Buck AK, Herrmann K, Schreyogg J. PET/CT for staging lung cancer: costly or cost-saving? Eur J Nucl Med Mol Imaging. 2011;38:799-801.
11. Schreyogg J, Weller J, Stargardt T, Herrmann K, Bluemel C, Dechow T, et al. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer. J Nucl Med. 2010;51:1668-75.
12. Delbeke D, Schoder H, Martin WH, Wahl RL. Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. Semin Nucl Med. 2009;39:308-40.
13. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 3.2012. http://www.nccn.org/professionals/physician-gls/pdf/ nscl.pdf. Accessed 31 Aug 2012.
14. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059-66.
15. Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2:593-602.
16. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706-14.
17. Gregory DL, Hicks RJ, Hogg A, Binns DS, Shum PL, Milner A, et al. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med. 2012;53:1007-15.
18. Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26:2155-61.
19. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med. 2008;49:1928-35.
20. Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME, et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med. 2002;43:752-6.
21. Nawara C, Rendl G, Wurstbauer K, Lackner B, Rettenbacher L, Datz L, et al. The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy. Q J Nucl Med Mol Imaging. 2012;56:191-201.
22. Win T, Miles K, Janes SM, Ganeshan B, Shastry M, Endozo R, et al. Tumor heterogeneity as measured on the CT component of PET/CT predicts survival in patients with potentially curable non-small cell lung cancer. Clin Cancer Res. 2013;19:1-9.
23. Kanzaki R, Higashiyama M, Fujiwara A, Tokunaga T, Maeda J, Okami J, et al. Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: risk factors, pattern, and histopathological study. Lung Cancer. 2011;71:333-7.
24. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 2009;361:32-9.
25. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011-9.
26. Song JW, Oh YM, Shim TS, Kim WS, Ryu JS, Choi CM. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer. 2009;65:333-8.
27. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380-8.